Abstract:BackgroundEfficient early detection methods for lung cancer can significantly decrease patient mortality. One promising approach is the use of tumor-associated autoantibodies (TAABs) as a diagnostic tool. In this study, the researchers aimed to evaluate the potential of seven TAABs in detecting lung cancer within a population undergoing routine health examinations. The results of this study could provide valuable insights into the utility of TAABs for lung cancer screening and diagnosis. MethodsIn this study, the serum concentrations of specific antibodies were measured using enzyme-linked immunosorbent assay (ELISA) in a cohort of 15,430 subjects. The efficacy of both a 7-TAAB panel and LDCT for lung cancer detection were evaluated through receiver operating characteristic (ROC) analyses, with sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) being assessed and compared. These results could have significant implications for the development of improved screening methods for lung cancer. ResultsOver the 12-month observation period, 26 individuals were diagnosed with lung cancer. The 7-TAAB panel demonstrated promising sensitivity (61.5%) and a high degree of specificity (88.5%). The panel's area under the receiver operating characteristic (ROC) curve was 0.8062, which was superior to that of any individual TAAB. In stage I patients, the sensitivity of the panel was 50%. In our cohort, there was no gender or age bias observed. This 7-TAAB panel showed a sensitivity of approximately 60% in detecting lung cancer, regardless of histological subtype or lesion size. Notably, ground-glass nodules had a higher diagnostic rate than solid nodules (83.3% vs. 36.4%, P = 0.021). The ROC analyses further revealed that the combination of LDCT with the 7-TAAB assay exhibited a significantly superior diagnostic efficacy than LDCT alone. ConclusionIn the context of the study, it was demonstrated that the 7-TAAB panel showed improved detective efficacy of LDCT, thus serving as an effective aid for the detection of lung cancer in real-world scenarios.

P2.11-08 Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /solid Nodules

Early Detection of Lung Cancer by Using an Autoantibody Panel in Chinese Population

Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

Development of an autoantibody panel for early detection of lung cancer in the Chinese population

The Diagnostic Value of a Seven‐autoantibody Panel and a Nomogram with a Scoring Table for Predicting the Risk of Non–small‐cell Lung Cancer

Early Detection of Lung Cancer in a Real-World Cohort Via Tumor-Associated Immune Autoantibody and Imaging Combination

Diagnostic value of multiple tumor-associated autoantibodies in lung cancer

Development of Diagnosis Model for Early Lung Nodules Based on a Seven Autoantibodies Panel and Imaging Features

Diagnostic value of tumor associated autoantibody panel in early detection of lung cancer in Chinese population: Protocol for a prospective, observational, and multicenter clinical trial

The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer

The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer

Seven tumor‐associated autoantibodies as a serum biomarker for primary screening of early‐stage non‐small cell lung cancer

Clinical Value of Seven Autoantibodies Against Tumor-Associated Antigens and Tumor Markers in Lung Cancer Patients: A Retrospective Analysis from a Single Institution

Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan

B-360 Usefulness of the Ratios of CYFRA21-1 and P53 Autoantibody Immune Complexes to Their Free Antigens in Lung Cancer

Five Tumor-Associated Autoantibodies Expression Levels in Serum Predict Lung Cancer and Associate with Poor Outcome.

Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array

The application of autoantibodies detection in the early diagnosis and screening of lung cancer

Can trastuzumab enhance the effectiveness of chemotherapy in patients with resected, HER2-positive, stage II/III, or stage IV gastric cancer?

Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)

Diagnostic Value of Serum 7-AABs Combined with CEA and CA199 in the Detection of Lung Cancer